EXPERIENCE

Capital Markets

John advises on various capital markets transactions, from IPOs and direct listings to follow-on offerings. His experience includes representing:

• Ceribell in its US$207 million IPO
• IDEAYA Biosciences in its follow-on equity public offerings
• Underwriters in the US$1.2 billion IPO of HashiCorp
• Aligos Therapeutics in its US$150 million IPO, and follow-on offering and PIPE transaction
• Financial advisors in the direct listing of Asana
• Initial purchasers in the Slack Technologies US$862 million convertible notes offering
• Financial advisors in the direct listing of Slack Technologies
• Revolution Medicines in its US$273.7 million IPO, and follow-on offerings and at-the-market offerings
• Ascendis Pharma in its US$124 million IPO, follow-on offerings, and royalty financings
• Underwriters in the US$80 million IPO of Harpoon Therapeutics
• Achaogen in its follow-on offerings, at-the-market equity offerings, and PIPE transaction
• Ardelyx in its PIPE transactions and at-the-market offerings
• Initial purchasers in the BioMarin Pharmaceutical US$495 million convertible notes offering
• Prothena Corporation in its US$155 million follow-on offering
• e.l.f. Beauty in its US$259 million public offering by selling stockholders
• Integrated Device Technology in its US$374 million convertible notes offering
• Relypsa in its US$87 million IPO, follow-on offering, and at-the-market equity offerings
• Initial purchasers in the Salesforce.com US$1.15 billion convertible notes offering
• Underwriters in the US$70 million IPO and follow-on offering of KaloBios Pharmaceuticals
• OncoMed Pharmaceuticals in its US$94 million IPO and at-the-market equity offering
• Corcept Therapeutics in its follow-on offering
• CytomX Therapeutics in its PIPE transaction
• Sarepta Therapeutics in its follow-on offering and its at-the-market equity offering

Company Representation and Venture Financings

John represents public and private companies in general corporate matters, public company reporting, venture capital financings, and strategic transactions. His clients include:

• 4D Molecular Therapeutics (public; biotech)
• Aligos Therapeutics (public; biotech)
• Ascendis Pharma (public; biotech)
• Ardelyx (public; biotech)
• Azora Therapeutics (private; biotech)
• Ceribell (public; medical device)
• Extreme Networks (public; tech)
• Fandom (private; tech)
• Intuitive Surgical (public; medical device)
• Modernizing Medicine (private; tech)
• National Resilience (private; biotech)
• Revolution Medicines (public; biotech)

Mergers and Acquisitions and Activism Defense

John has advised on the following M&A and activism defense matters:

• e.l.f. Beauty (public) in its cooperation agreement with Marathon Partners
• Fandom (private) in acquisition of Huddler
• Mirna Therapeutics (public) in its reverse merger transaction with Synlogic
• OpenTable (public) in acquisition of Foodspotting
• Pearl Therapeutics (private) in its sale to AstraZeneca
• Relypsa (public) in its sale to Galenica Group
• Revolution Medicines (public) in its acquisition of EQRx